Re: Employment Offer LetterBoundless Bio, Inc. • March 6th, 2024 • Pharmaceutical preparations
Company FiledMarch 6th, 2024 Industry• DUTIES. You shall perform such duties as are customarily associated with the position of Chief Medical Officer, reporting into the CEO, and such other duties as are assigned to you by your supervisor. You shall perform your services on a full-time basis at the Company’s headquarters. This is an exempt position, meaning that you are not eligible for overtime compensation.
Re: Amended and Restated Employment Offer LetterParticipation Agreement • March 6th, 2024 • Boundless Bio, Inc. • Pharmaceutical preparations • California
Contract Type FiledMarch 6th, 2024 Company Industry JurisdictionYou are currently a party to an amended and restated employment offer letter with Boundless Bio, Inc. (the “Company”) dated January 1, 2020 (the “Prior Agreement”). You and the Company hereby agree to amend and restate the Prior Agreement to memorialize the terms of your continued employment with the Company, as provided in this amended and restated employment letter agreement (this “Amended Agreement”), effective as of the date on which the Company consummates its initial public offering (“IPO”). In the event the IPO does not occur, this Amended Agreement shall not become effective and the Prior Agreement shall continue in full force and effect.
Re: Amended and Restated Employment Offer LetterParticipation Agreement • March 6th, 2024 • Boundless Bio, Inc. • Pharmaceutical preparations • New York
Contract Type FiledMarch 6th, 2024 Company Industry JurisdictionYou are currently a party to an employment offer letter with Boundless Bio, Inc. (the “Company”) dated July 7, 2023 (the “Prior Agreement”). You and the Company hereby agree to amend and restate the Prior Agreement to memorialize the terms of your continued employment with the Company, as provided in this amended and restated employment letter agreement (this “Amended Agreement”), effective as of the date on which the Company consummates its initial public offering (“IPO”). In the event the IPO does not occur, this Amended Agreement shall not become effective and the Prior Agreement shall continue in full force and effect.